Free tool
FAERS Monitor: Elahere
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761310 or its brand name (Elahere, Mirvetuximab Soravtansine-Gynx). Reports on generic versions are filed under their own applications.
Reports
1,814
Serious
1,057
58% of reports
Hospitalization
300
Death reported
236
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death131
- neuropathy peripheral120
- vision blurred120
- disease progression108
- diarrhoea103
- abdominal pain101
- nausea97
- pneumonitis95
- cataract90
- fatigue68
- keratopathy60
- dry eye59
- vomiting58
- keratitis55
- visual impairment55
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 6 |
| 2023 | 366 |
| 2024 | 397 |
| 2025 | 529 |
| 2026 | 514 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,345 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| keratopathySignal | 60 | 457.2 | 354.7 | 25,842 |
| keratitisSignal | 55 | 213.6 | 164.3 | 11,223 |
| pneumonitisSignal | 95 | 40.6 | 33.4 | 3,621 |
| cataractSignal | 90 | 17.5 | 14.3 | 1,390 |
| neuropathy peripheralSignal | 120 | 14.6 | 12.3 | 1,517 |
| dry eyeSignal | 59 | 13.7 | 10.7 | 684 |
| disease progressionSignal | 108 | 10.6 | 8.8 | 933 |
| vision blurredSignal | 120 | 10.1 | 8.5 | 985 |
| visual impairmentSignal | 55 | 5.1 | 4.0 | 181 |
| abdominal painSignal | 101 | 5.0 | 4.2 | 326 |
| diarrhoea | 103 | 1.9 | 1.5 | 41 |
| death | 131 | 1.8 | 1.5 | 44 |
| vomiting | 58 | 1.4 | 1.1 | 7 |
| nausea | 97 | 1.4 | 1.2 | 12 |
| fatigue | 68 | 1.0 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.